A highly cited paper entitled, 'Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial', published in the International Journal of Antimicrobial Agents (IJAA, Int J Antimicrob Agents) was notified by the Journal Editor in chief as not meeting "the Society’s expected standard, especially relating to the lack of better explanations of the inclusion criteria and the triage of patients to ensure patient safety."
The notice further notes that the article was not peer-reviewed as per industry's peer review rules and the process was handled by an Associate Editor.
The full Notice is below and the online link is here.
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial (Gautret P et al. PMID 32205204)
ISAC shares the concerns regarding the above article published recently in the International Journal of Antimicrobial Agents (IJAA). The ISAC Board believes the article does not meet the Society’s expected standard, especially relating to the lack of better explanations of the inclusion criteria and the triage of patients to ensure patient safety.
Despite some suggestions online as to the reliability of the article's peer review process, the process did adhere to the industry's peer review rules. Given his role as Editor in Chief of this journal, Jean-Marc Rolain had no involvement in the peer review of the manuscript and has no access to information regarding its peer review. Full responsibility for the manuscript's peer review process was delegated to an Associate Editor.
Although ISAC recognises it is important to help the scientific community by publishing new data fast, this cannot be at the cost of reducing scientific scrutiny and best practices. Both Editors in Chief of our journals (IJAA and Journal of Global Antimicrobial Resistance) are in full agreement.
Andreas Voss
ISAC President
Original Article doi: 10.1016/j.ijantimicag.2020.105949
